Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor.
Hematology
; 28(1): 2220521, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-37278609
ABSTRACT
OBJECTIVE:
To analyze the effect of granulocyte colony-stimulating factor (G-CSF) on outcomes in patients with acute myeloid leukemia (AML).METHODS:
A total of 526 patients with AML in the Haematology Department were enrolled. They were divided into a G-CSF treatment group and a no G-CSF group according to whether G-CSF was administered in the induction chemotherapy period, with 355 cases in the G-CSF group and 171 cases in the no G-CSF group. Cox regression analysis and Kaplan-Meier curve analysis were used to analyze the effect of G-CSF on the first complete remission (CR1) phase and overall survival (OS). In addition, further analysis was performed based on an initial white blood cell count of 50 * 10^9/L.RESULTS:
The application of G-CSF significantly shortened the CR1 phase and OS in patients with high leukocytes.CONCLUSIONS:
G/GM-CSF should be used with caution in patients with AML, especially those with high leukocytes.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
/
Protocolos de Quimioterapia Combinada Antineoplásica
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article